Skip to main content
SpringerLink
Log in

Contraception in Perimenopausal Patients

  • Chapter
  • First Online:
The Handbook of Contraception

Part of the book series: Current Clinical Practice ((CCP))

  • 770 Accesses

Abstract

People of older reproductive age may still require contraception to prevent unintended pregnancy. An individual’s preferences and values should be considered during contraceptive counseling, and anticipatory guidance on the perimenopausal transition should also be discussed. Age alone is not a contraindication to the use of any contraceptive method; however, certain medical conditions and comorbidities may limit the use of certain methods. Outside of these considerations, contraception can be safely used by perimenopausal persons until menopause or age 55. In addition to preventing pregnancy, hormonal contraception has several important noncontraceptive health benefits in this age group. Furthermore, perimenopause may be characterized by irregular menses and vasomotor symptoms, which may be improved by hormonal contraception.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grady D. Management of menopausal symptoms. N Engl J Med. 2006;355(22):2338–47.

    CAS  PubMed  Google Scholar 

  2. Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metabol. 2007;92(8):3060–7.

    CAS  Google Scholar 

  3. Monte LM, Ellis RR. Fertility of women in the United States: 2012. Econ. 2014;24:1071–100.

    Google Scholar 

  4. Sonfield A, Hasstedt K, Gold RB. Moving forward: family planning in the era of health reform. 2014.

    Google Scholar 

  5. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med. 2016;374(9):843–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Balasch J, Gratacos E. Delayed childbearing: effects on fertility and the outcome of pregnancy. Curr Opin Obstet Gynecol. 2012;24(3):187–93.

    PubMed  Google Scholar 

  7. Shifren JL, Gass ML, Group NRfCCoMWW. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038–62.

    PubMed  Google Scholar 

  8. Dehlendorf C, Levy K, Kelley A, Grumbach K, Steinauer J. Women’s preferences for contraceptive counseling and decision making. Contraception. 2013;88(2):250–6.

    PubMed  Google Scholar 

  9. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. US selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(4):1–72.

    Google Scholar 

  10. Roberts A, Noyes J. Contraception and women over 40 years of age: mixed-method systematic review. J Adv Nurs. 2009;65(6):1155–70.

    PubMed  Google Scholar 

  11. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. US medical eligibility criteria for contraceptive use, 2016. 2016.

    Google Scholar 

  12. Sundaram A, Vaughan B, Kost K, Bankole A, Finer L, Singh S, et al. Contraceptive failure in the United States: estimates from the 2006-2010 National Survey of Family Growth. Perspect Sex Reprod Health. 2017;49(1):7–16.

    PubMed  PubMed Central  Google Scholar 

  13. Bitzer J. Overview of perimenopausal contraception. Climacteric: J Int Menopause Soc. 2019;22(1):44–50.

    CAS  Google Scholar 

  14. American College of Obstetricians Gynecologists. Practice Bulletin No. 186: long-acting reversible contraception: implants and intrauterine devices. Obs Gynecol. 2017;130(5):e251.

    Google Scholar 

  15. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP) Knowledge for Health Project. Family planning: a global handbook for providers (2018 update). Baltimore/Geneva: CCP and WHO; 2018.

    Google Scholar 

  16. Lewis RA, Taylor D, Natavio MF, Melamed A, Felix J, Mishell D Jr. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception. 2010;82(6):491–6.

    CAS  PubMed  Google Scholar 

  17. Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception. 1990;41(4):353–62.

    CAS  PubMed  Google Scholar 

  18. Bednarek PH, Jensen JT. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Women’s Health. 2010;1:45–58.

    Google Scholar 

  19. Seeber B, Ziehr SC, Gschliebetaer A, Moser C, Mattle V, Seger C, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception. 2012;86(4):345–9.

    CAS  PubMed  Google Scholar 

  20. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007;75(6):S16–30.

    CAS  PubMed  Google Scholar 

  21. Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception. 2014;89(6):495–503.

    PubMed  Google Scholar 

  22. Andrade AT, Pizarro E, Shaw ST Jr, Souza JP, Belsey EM, Rowe PJ. Consequences of uterine blood loss caused by various intrauterine contraceptive devices in South American women. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1988;38(1):1–18.

    CAS  PubMed  Google Scholar 

  23. Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke. 2009;40(4):1059–62.

    CAS  PubMed  Google Scholar 

  24. Chakhtoura Z, Canonico M, Gompel A, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab. 2011;96(4):1169–74.

    CAS  PubMed  Google Scholar 

  25. Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod (Oxford, England). 2016;31(11):2491–8.

    CAS  Google Scholar 

  26. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obs Gynecol. 2017;216(6):586.e1-.e6.

    Google Scholar 

  27. Makarainen L, van Beek A, Tuomivaara L, Asplund B, Coelingh BH. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril. 1998;69(4):714–21.

    CAS  PubMed  Google Scholar 

  28. Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception. 2011;83(3):202–10.

    CAS  PubMed  Google Scholar 

  29. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105–13.

    PubMed  PubMed Central  Google Scholar 

  30. Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception. 2011;83(5):426–30.

    CAS  PubMed  Google Scholar 

  31. Kowal D, Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, et al. Contraceptive technology 21st edition: managing contraception, LLC; 2018.

    Google Scholar 

  32. Gardner JM, Mishell DR Jr. Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive. Fertil Steril. 1970;21(4):286–91.

    CAS  PubMed  Google Scholar 

  33. Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception. 1988;38(2):181–206.

    CAS  PubMed  Google Scholar 

  34. Mishell DR Jr, Kletzky OA, Brenner PF, Roy S, Nicoloff J. The effect of contraceptive steroids on hypothalamic-pituitary function. Am J Obstet Gynecol. 1977;128(1):60–74.

    CAS  PubMed  Google Scholar 

  35. Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception. 2013;87(5):611–24.

    PubMed  Google Scholar 

  36. Mishell DR, Shoupe D. The Handbook of contraception: a guide for practical management. New York: Humana Press; 2016.

    Google Scholar 

  37. Speroff L, Darney P. A clinical guide for contraception. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.

    Google Scholar 

  38. Kovacs G. Progestogen-only pills and bleeding disturbances. Hum Reprod (Oxford, England). 1996;11(Suppl 2):20–3.

    Google Scholar 

  39. Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;(8)

    Google Scholar 

  40. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception. 2007;75(5):328–36.

    PubMed  Google Scholar 

  41. van Hylckama VA, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ (Clinical research ed). 2009;339:b2921.

    Google Scholar 

  42. Dragoman MV, Tepper NK, Fu R, Curtis KM, Chou R, Gaffield ME. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287–94.

    PubMed  PubMed Central  Google Scholar 

  43. Curtis KM, Mohllajee AP, Peterson HB. Regret following female sterilization at a young age: a systematic review. Contraception. 2006;73(2):205–10.

    PubMed  Google Scholar 

  44. Berer M. Dual protection: more needed than practised or understood. Reprod Health Matters. 2006;14(28):162–70.

    PubMed  Google Scholar 

  45. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod (Oxford, England). 2012;27(7):1994–2000.

    Google Scholar 

  46. Hsia JK, Creinin MD. Intrauterine Contraception. Semin Reprod Med. 2016;34(3):175–82.

    PubMed  Google Scholar 

  47. Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet (London, England). 2010;375(9714):555–62.

    CAS  Google Scholar 

  48. Baldwin MK, Jensen JT. Contraception during the perimenopause. Maturitas. 2013;76(3):235–42.

    PubMed  Google Scholar 

  49. American College of Obstetricians Gynecologists. Diagnosis of abnormal uterine bleeding in reproductive-aged women. Pract Bull. 2012;(128):197–206.

    Google Scholar 

  50. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv. 2002;57(2):120–8.

    PubMed  Google Scholar 

  51. Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2015;(4):Cd002126.

    Google Scholar 

  52. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65(2):129–32.

    CAS  PubMed  Google Scholar 

  53. Carvalho NM, Chou V, Modesto W, Margatho D, Garcia EAL, Bahamondes L. Relationship between user satisfaction with the levonorgestrel-releasing intrauterine system and bleeding patterns. J Obstet Gynaecol Res. 2017;43(11):1732–7.

    CAS  PubMed  Google Scholar 

  54. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994;49(1):56–72.

    CAS  PubMed  Google Scholar 

  55. Kelekci S, Kelekci KH, Yilmaz B. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis. Contraception. 2012;86(5):458–63.

    CAS  PubMed  Google Scholar 

  56. Kriplani A, Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116(1):35–8.

    CAS  PubMed  Google Scholar 

  57. Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. Contraception. 2007;75(6 Suppl):S130–3.

    CAS  PubMed  Google Scholar 

  58. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2009;113(5):1104–16.

    PubMed  Google Scholar 

  59. Sangi-Haghpeykar H, Poindexter AN 3rd, Bateman L, Ditmore JR. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996;88(2):227–33.

    CAS  PubMed  Google Scholar 

  60. Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2:Cd000154.

    PubMed  Google Scholar 

  61. Edelman A, Micks E, Gallo MF, Jensen JT, Grimes DA. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014;7:Cd004695.

    Google Scholar 

  62. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 μg versus >20 μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;(8)

    Google Scholar 

  63. Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med. 2008;358(12):1262–70.

    CAS  PubMed  Google Scholar 

  64. Shargil AA. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: a three-year prospective study. Int J Fertil. 1985;30(1):15, 8-28

    CAS  PubMed  Google Scholar 

  65. Blumel JE, Castelo-Branco C, Binfa L, Aparicio R, Mamani L. A scheme of combined oral contraceptives for women more than 40 years old. Menopause. 2001;8(4):286–9.

    CAS  PubMed  Google Scholar 

  66. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:Cd004143.

    PubMed  Google Scholar 

  67. Bullock JL, Massey FM, Gambrell RD Jr. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol. 1975;46(2):165–8.

    CAS  PubMed  Google Scholar 

  68. Morrison JC, Martin DC, Blair RA, Anderson GD, Kincheloe BW, Bates GW, et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol. 1980;138(1):99–104.

    CAS  PubMed  Google Scholar 

  69. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv. 2004;59(5):368–78.

    PubMed  Google Scholar 

  70. Weiderpass E, Adami H-O, Baron JA, Magnusson C, Bergström R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91(13):1131–7.

    CAS  PubMed  Google Scholar 

  71. Kim JJ, Chapman-Davis E, editors. Role of progesterone in endometrial cancer. Seminars in reproductive medicine: © Thieme Medical Publishers; 2010.

    Google Scholar 

  72. Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, et al. Intrauterine devices and endometrial cancer risk: a pooled analysis of the epidemiology of endometrial cancer consortium. Int J Cancer. 2015;136(5):E410–22.

    CAS  PubMed  Google Scholar 

  73. Jareid M, Thalabard JC, Aarflot M, Bovelstad HM, Lund E, Braaten T. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018;149(1):127–32.

    CAS  PubMed  Google Scholar 

  74. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Marnach ML, Butler KA, Henry MR, Hutz CE, Langstraat CL, Lohse CM, et al. Oral progestogens versus levonorgestrel-releasing intrauterine system for treatment of endometrial intraepithelial neoplasia<sup/>. J Women’s Health (2002). 2017;26(4):368–73.

    Google Scholar 

  76. Dolapcioglu K, Boz A, Baloglu A. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study. Clin Exp Obstet Gynecol. 2013;40(1):122–6.

    CAS  PubMed  Google Scholar 

  77. Miller TA, Allen RH, Kaunitz AM, Cwiak CA. Contraception for midlife women: a review. Menopause. 2018;25(7):817–27.

    PubMed  Google Scholar 

  78. Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric: J Int Menopause Soc. 2015;18(4):470–82.

    CAS  Google Scholar 

  79. Sitruk-Ware R. Routes of delivery for progesterone and progestins. Maturitas. 2007;57(1):77–80.

    CAS  PubMed  Google Scholar 

  80. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009;(4):Cd007245.

    Google Scholar 

  81. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA. 1987;257(6):796–800.

    Google Scholar 

  82. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer. 2010;17(4):R263–71.

    CAS  PubMed  Google Scholar 

  83. MacKintosh ML, Crosbie EJ. Prevention strategies in endometrial carcinoma. Curr Oncol Rep. 2018;20(12):101.

    PubMed  PubMed Central  Google Scholar 

  84. World Health Organization. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO collaborative study of neoplasia and steroid contraceptives. Int J Cancer. 1991;49(2):186–90.

    Google Scholar 

  85. Lentz GM, Lobo RA, Gershenson DM, Katz VL. Comprehensive gynecology e-book: Elsevier Health Sciences; 2012.

    Google Scholar 

  86. Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014;124(2 Pt 1):292–9.

    CAS  PubMed  Google Scholar 

  87. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008;9(12):1191–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(1):139–47.

    CAS  PubMed  Google Scholar 

  89. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obs Gynecol. 2017;216(6):580.e1–9.

    Google Scholar 

  90. Wilailak S, Vipupinyo C, Suraseranivong V, Chotivanich K, Kietpeerakool C, Tanapat Y, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG. 2012;119(6):672–7.

    CAS  PubMed  Google Scholar 

  91. Kaunitz A. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. 1996;41(5 Suppl):419–27.

    CAS  PubMed  Google Scholar 

  92. Wang C, Liang Z, Liu X, Zhang Q, Li S. The association between endometriosis, tubal ligation, hysterectomy and epithelial ovarian cancer: meta-analyses. Int J Environ Res Publ Health. 2016;13(11).

    Google Scholar 

  93. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer. 2001;84(5):722–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–39.

    PubMed  Google Scholar 

  95. Cancer CGoHFiB. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713–27.

    Google Scholar 

  96. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025–32.

    CAS  PubMed  Google Scholar 

  97. Samson M, Porter N, Orekoya O, Hebert JR, Adams SA, Bennett CL, et al. Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat. 2016;155(1):3–12.

    CAS  PubMed  Google Scholar 

  98. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet (London, England). 2011;377(9773):1276–87.

    CAS  Google Scholar 

  99. Rizzoli R, Bonjour JP. Hormones and bones. Lancet (London, England). 1997;349(Suppl 1):sI20–3.

    Google Scholar 

  100. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet (London, England). 1999;353(9163):1481–4.

    CAS  Google Scholar 

  101. Beksinska ME, Kleinschmidt I, Smit JA. Bone mineral density in midlife long-term users of hormonal contraception in South Africa: relationship with obesity and menopausal status. Women’s Midlife Health. 2018;4:6.

    PubMed  PubMed Central  Google Scholar 

  102. Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception. 2010;81(3):209–14.

    CAS  PubMed  Google Scholar 

  103. Massai R, Makarainen L, Kuukankorpi A, Klipping C, Duijkers I, Dieben T. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. Hum Reprod (Oxford, England). 2005;20(10):2764–8.

    CAS  Google Scholar 

  104. Isley MM, Kaunitz AM. Update on hormonal contraception and bone density. Rev Endocr Metab Disord. 2011;12(2):93–106.

    CAS  PubMed  Google Scholar 

  105. Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev. 2014;(6):Cd006033.

    Google Scholar 

  106. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74(2):90–9.

    CAS  PubMed  Google Scholar 

  107. Kaunitz AM, Peipert JF, Grimes DA. Injectable contraception: issues and opportunities. Contraception. 2014;89(5):331–4.

    PubMed  Google Scholar 

  108. Lanza LL, McQuay LJ, Rothman KJ, Bone HG, Kaunitz AM, Harel Z, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121(3):593–600.

    CAS  PubMed  Google Scholar 

  109. Lichtmacher A, Adams M, Berga S. Guidelines for women’s health care: a resource manual. Washington, DC: American College of Obstetricians and Gynecologists; 2014.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of GYN/OB, Emory University School of Medicine, Atlanta, GA, USA

    Jennifer Reeves & Carrie Cwiak

Authors
  1. Jennifer Reeves
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carrie Cwiak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carrie Cwiak .

Editor information

Editors and Affiliations

  1. Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Donna Shoupe

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reeves, J., Cwiak, C. (2020). Contraception in Perimenopausal Patients. In: Shoupe, D. (eds) The Handbook of Contraception. Current Clinical Practice. Humana, Cham. https://doi.org/10.1007/978-3-030-46391-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-46391-5_17

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-46390-8

  • Online ISBN: 978-3-030-46391-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation